- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.03. | Xilio Therapeutics reports Q4 results | 2 | Seeking Alpha | ||
| 11.03. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.03. | Xilio Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 11.03. | Xilio advances cancer treatments, secures AbbVie collaboration | 7 | Investing.com | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.03. | Xilio Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results | 123 | GlobeNewswire (Europe) | Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T... ► Artikel lesen | |
| 14.02. | AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn | 10 | PMLiVE | ||
| 13.02. | AbbVie and Xilio to collaborate on antibody-based immunotherapies | 6 | Pharmaceutical Technology | ||
| 12.02. | Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? | 3 | Benzinga.com | ||
| 12.02. | AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal | 12 | FierceBiotech | ||
| 12.02. | AbbVie, Xilio Hook up | 4 | Baystreet.ca | ||
| 12.02. | AbbVie and Xilio Therapeutics announce collaboration and option agreement | 7 | Seeking Alpha | ||
| 12.02. | AbbVie, Xilio Partner To Develop Novel Tumor-Activated Immunotherapies; Stock Up In Pre-market | 11 | RTTNews | ||
| 12.02. | Xilio-Aktien schnellen nach Kooperationsvereinbarung mit AbbVie in die Höhe | 4 | Investing.com Deutsch | ||
| 12.02. | Xilio shares soar on AbbVie collaboration deal | 5 | Investing.com | ||
| 12.02. | AbbVie und Xilio kooperieren bei tumoraktivierten Therapien | 7 | Investing.com Deutsch | ||
| 12.02. | Xilio Therapeutics, Inc.; AbbVie Inc.: AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies | 206 | GlobeNewswire (Europe) | Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor... ► Artikel lesen | |
| 12.02. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs | 172 | GlobeNewswire (Europe) | Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended... ► Artikel lesen | |
| 12.02. | AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies | 175 | PR Newswire | Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell... ► Artikel lesen | |
| 12.02. | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,499 | +1,63 % | Palatin: Bremelanotide-Tirzepatide Combination Achieves Primary Endpoint In Phase 2 Obesity Study | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The... ► Artikel lesen | |
| BIOXXMED | 0,800 | +107,25 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| ORGANOVO | 2,140 | 0,00 % | Organovo, Inc.: Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements | SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| OCUGEN | 0,597 | -6,14 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA ZSB: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSIRONA BIOCHEM CORP.... ► Artikel lesen | |
| BIO-GATE | 0,760 | 0,00 % | Bio-Gate: Vielversprechende Wachstumschancen | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im Geschäftsjahr 2024 (per 31.12.) einen leichten Umsatzrückgang verbucht, besitzt aufgrund der innovativen... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,662 | -5,43 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
| VAXART | 0,347 | +6,17 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,280 | -0,71 % | Cellectar Biosciences: Multibagger mit Ansage? | Cellectar Biosciences (WKN: A3DQSD) heißt unsere Top-Spekulation der Stunde. Das auf Radiopharmaka gegen Krebs spezialisierte Biotechunternehmen konnte gestern eine wichtige Einigung mit der US-Gesundheitsbehörde... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,059 | -0,67 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| AFFIMED | 0,930 | -100,00 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting | MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,... ► Artikel lesen | |
| IMMUNIC | 0,943 | -8,27 % | EQS-News: Immunic AG: Immunic, Inc. to Participate in Scientific and Industry Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
01.04.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,104 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,076 | -6,17 % | T2 Biosystems, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| CEL-SCI | 0,197 | +0,77 % | CEL-SCI Aktie: Risiken mehren sich | CEL-SCI hat am 18. März 2025 den Abschluss eines Finanzierungsangebots in Höhe von 2,5 Millionen Dollar bekannt gegeben. Dabei wurden 16 Millionen Stammaktien oder vorfinanzierte Optionsscheine ausgegeben.... ► Artikel lesen |
Das Unternehmen XILIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,011 (-1,53 %) liegt der Kurs bei 0,719 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.
